公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2002 | Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells | Chuang S.-E.; Yeh P.-Y.; YEN-SHEN LU ; Lai G.-M.; Liao C.-M.; Gao M.; ANN-LII CHENG | Biochemical Pharmacology | 161 | 138 | |
2010 | Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma | Chiang C.-T.; Yeh P.-Y.; Gao M.; Chen C.-W.; Yeh L.-C.; Feng W.-C.; SUNG-HSIN KUO ; CHIH-HUNG HSU ; YEN-SHEN LU ; ANN-LII CHENG | Cancer Letters | 19 | 19 | |
2004 | Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy | CHIH-HUNG HSU ; Hsu H.-C.; Chen H.-L.; Gao M.; Yeh P.-Y.; PEI-JER CHEN ; ANN-LII CHENG | Anticancer Research | 47 | 41 | |
2015 | Dual Phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer | YU-HSUAN CHEN ; Wei M.-F.; CHUN-WEI WANG ; Lee H.-W.; Pan S.-L.; Gao M.; SUNG-HSIN KUO ; ANN-LII CHENG ; Teng C.-M. | Cancer letters | 42 | 39 | |
2006 | Glucocorticoids enhance cytotoxicity of cisplatin via suppression of NF-κB activation in the glucocorticoid receptor-rich human cervical carcinoma cell line SiHa | YEN-SHEN LU ; Yeh P.-Y.; Chuang S.-E.; Gao M.; Kuo M.-L.; ANN-LII CHENG | Journal of Endocrinology | 23 | 21 | |
2002 | Induction of Epstein-Barr virus (EBV) reactivation in Raji cells by doxorubicin and cisplatin | CHIH-HUNG HSU ; Hergenhahn M.; Chuang S.-E.; Yeh P.-Y.; Wu T.-C.; Gao M.; ANN-LII CHENG | Anticancer Research | 15 | 13 | |
2005 | Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro | CHIH-HUNG HSU ; Gao M.; Chen C.-L.; Yeh P.-Y.; ANN-LII CHENG | Oncology | 39 | 37 | |
2011 | Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001 | SUNG-HSIN KUO ; CHIH-HUNG HSU ; Chen L.-T.; YEN-SHEN LU ; Lin C.-H.; Yeh P.-Y.; Jeng H.-J.; Gao M.; KUN-HUEI YEH ; ANN-LII CHENG | European Journal of Cancer | 17 | 17 | |
2008 | NF-κB p50 promotes tumor cell invasion through negative regulation of invasion suppressor gene CRMP-1 in human lung adenocarcinoma cells | Gao M.; Yeh P.Y.; YEN-SHEN LU ; Chang W.C.; Kuo M.-L.; ANN-LII CHENG | Biochemical and Biophysical Research Communications | 23 | 19 | |
2008 | OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma | Gao M.; Yeh P.Y.; YEN-SHEN LU ; CHIH-HUNG HSU ; Chen K.-F.; Lee W.-C.; Feng W.-C.; Chen C.-S.; Kuo M.-L.; ANN-LII CHENG | Cancer Research | 131 | 123 | |
2006 | A pathway for tumor necrosis factor-α-induced Bcl10 nuclear translocation: Bcl10 is up-regulated by NF-κB and phosphorylated by Akt1 and then complexes with Bcl3 to enter the nucleus | Pei Y.Y.; SUNG-HSIN KUO ; KUN-HUEI YEH ; Chuang S.-E.; CHIH-HUNG HSU ; Wen C.C.; Lin H.-I.; Gao M.; ANN-LII CHENG | Journal of Biological Chemistry | 43 | 39 | |
2021 | A phase ib study of alpelisib or buparlisib combined with tamoxifen plus goserelin in premenopausal women with HR-positive HER2-negative advanced breast cancer | YEN-SHEN LU ; Lee K.S.; Chao T.-Y.; Tseng L.-M.; Chitapanarux I.; Chen S.-C.; Liu C.-T.; Sohn J.; Kim J.H.; Chang Y.-C.; Yang Y.; Shotelersuk K.; Jung K.H.; Valenti R.; Slader C.; Gao M.; Park Y.H. | Clinical Cancer Research | 23 | 16 | |
2012 | Radiosensitizing effect of a phenylbutyrate-derived histone deacetylase inhibitor in hepatocellular carcinoma | YEN-SHEN LU ; Chou C.-H.; KAI-YUAN TZEN ; Gao M.; ANN-LII CHENG ; Kulp S.K.; CHIA-HSIEN CHENG | International Journal of Radiation Oncology Biology Physics | 21 | 20 | |
2014 | Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma | Liu W.-L.; Gao M.; KAI-YUAN TZEN ; CHIAO-LING TSAI ; Feng-Ming Hsu ; ANN-LII CHENG ; CHIA-HSIEN CHENG | Oncotarget | 38 | 39 |